Sydnexis Announces New Data from Phase 3 STAR Trial of SYD-101 Presented at 2026 AAPOS Annual Meeting

Comprehensive analyses identified children aged 3 to 12 years and fast progressors with mild to moderate myopia as the populations with greatest treatment benefit  Data demonstrated consistent effects in the largest global pediatric myopia clinical trial to date  SYD-101 well tolerated with no unexpected atropine-related adverse events     DEL MAR, Calif., March 23, 2026 – Sydnexis, Inc., a biopharmaceutical company focused on developing a novel […]